Expertise in
2
conditions

Satoru Motoyama

Akita, JP 
Expertise in
2
conditions
Akita, JP 
OverviewLocationsClinical Research

Overview

Satoru Motoyama practices in Akita, Japan. Mr. Motoyama is highly rated in 2 conditions, according to our data. His top areas of expertise are Esophageal Cancer, Gastroesophageal Junction Cancer, Lung Cancer, Lymphadenectomy, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 142 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Akita, Japan
Other Locations
Hondo, 0108543, Japan
Sayama, Japan
Tokyo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3

142 Total Publications

Lymph node metastasis risk in submucosal invasive gastric cancer based on C-reactive protein gene polymorphism analysis.
Lymph node metastasis risk in submucosal invasive gastric cancer based on C-reactive protein gene polymorphism analysis.
Journal: International journal of clinical oncology
Published: March 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Motoyama's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile